GenSight Biologics announced that recent prospective real-world data from early access programs confirm the benefit of LUMEVOQ® in patients with Leber Hereditary Optic Neuropathy from the ND4 mutation, as observed in clinical trials.
GenSight Biologics announced that recent prospective real-world data from early access programs confirm the benefit of LUMEVOQ® in patients with Leber Hereditary Optic Neuropathy from the ND4 mutation, as observed in clinical trials.